NCT01438424View on ClinicalTrials.gov

Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials

PHASE2CompletedINTERVENTIONAL
Enrollment

1,053

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

December 31, 2009

Study Completion Date

April 30, 2011

Conditions
Hepatitis B VirusHBV
Interventions
DRUG

Entecavir

Tablets, Oral, 1.0 mg, once daily

DRUG

Lamivudine

Oral, 100 mg, daily

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01438424 - Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials | Biotech Hunter | Biotech Hunter